arsenic trioxide has been researched along with Bladder Cancer in 17 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 1 (5.88) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 11 (64.71) | 29.6817 |
| 2010's | 5 (29.41) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Li, Q; Li, Y; Liu, H; Liu, R; Shen, X; Wang, W; Yu, G | 1 |
| Dalley, CD; Ezaydi, Y; Goepel, JR; Kirkbride, P; Krishna, R; Smith, DJ; Snowden, JA; Sorour, Y | 1 |
| An, R; Dong, X; Duan, G; Pan, S; Sun, X; Wang, Y | 1 |
| Bajorin, DF; Halabi, S; Small, E | 1 |
| Cao, L; Dunlevy, JR; Garrett, SH; Sens, DA; Sens, MA; Somji, S; Zheng, Y; Zhou, XD | 1 |
| Barhoumi, R; Burghardt, R; Chadalapaka, G; Jutooru, I; Lei, P; Safe, S; Sreevalsan, S | 1 |
| An, RH; Cao, Y; Ding, Q; Guo, GY; Wang, Y; Yu, SL | 1 |
| Liu, JH; Wan, YB; Wang, QH; Zhou, J | 1 |
| Chen, J; Guan, JY; Hour, TC; Huang, CY; Lu, SH; Pu, YS | 2 |
| Lu, G; Tong, Q; Zeng, F; Zhu, Z | 1 |
| Lin, C; Xing, S; Zhu, Z | 1 |
| Chen, J; Guan, JY; Hour, TC; Huang, CY; Lee, JM; Lin, CC; Pu, YS | 1 |
| Gao, X; Li, C; Tong, QS; Xie, SS; Yu, LZ; Zeng, FQ; Zhou, J | 1 |
| Low-Beer, TS; Robertson, DA | 1 |
| Chen, YC; Huan, SY; Yang, CH | 1 |
| Lu, G; Tong, Q; Zeng, F; Zhao, J; Zheng, L | 1 |
1 review(s) available for arsenic trioxide and Bladder Cancer
| Article | Year |
|---|---|
Arsenic trioxide therapy for relapsed acute promyelocytic leukemia: an useful salvage therapy.
Topics: Acute Kidney Injury; Antineoplastic Agents; Apoptosis; Arrhythmias, Cardiac; Arsenic Trioxide; Arsenicals; Cell Differentiation; Chemical and Drug Induced Liver Injury; Drug Evaluation; Drug Screening Assays, Antitumor; Gastrointestinal Neoplasms; Humans; Leukemia, Promyelocytic, Acute; Life Tables; Medicine, Chinese Traditional; Mitochondria; Models, Biological; Neoplasm Proteins; Neoplastic Stem Cells; Neuromuscular Diseases; Oncogene Proteins, Fusion; Oxides; Remission Induction; Salvage Therapy; Survival Analysis; Treatment Outcome; Tumor Cells, Cultured; Urinary Bladder Neoplasms | 2000 |
1 trial(s) available for arsenic trioxide and Bladder Cancer
| Article | Year |
|---|---|
Arsenic trioxide in recurrent urothelial cancer: a cancer and leukemia group B phase II trial (CALGB 99903).
Topics: Aged; Aged, 80 and over; Antineoplastic Agents; Arsenic Trioxide; Arsenicals; Female; Humans; Leukemia, Promyelocytic, Acute; Male; Middle Aged; Oxides; Recurrence; Survival Analysis; Treatment Outcome; Urinary Bladder Neoplasms; Urologic Neoplasms; Urothelium | 2009 |
15 other study(ies) available for arsenic trioxide and Bladder Cancer
| Article | Year |
|---|---|
Construction of a BALB/c-Nu Mouse Model of Invasive Bladder Carcinoma and Preliminary Studies on the Treatment of Bladder Tumors through Internal Iliac Arterial Infusion of Albumin-Bound Arsenic Trioxide (As2O3).
Topics: Animals; Arsenic Trioxide; Arsenicals; Carcinoma; Cell Line, Tumor; Disease Models, Animal; Humans; Infusions, Intra-Arterial; Mice; Mice, Inbred BALB C; Oxides; Serum Albumin, Bovine; Urinary Bladder Neoplasms; Xenograft Model Antitumor Assays | 2015 |
Histopathological response of transitional cell carcinoma to arsenic trioxide during the treatment of concurrently diagnosed acute promyelocytic leukaemia.
Topics: Antineoplastic Combined Chemotherapy Protocols; Arsenic Trioxide; Arsenicals; Carcinoma, Transitional Cell; Female; Humans; Leukemia, Promyelocytic, Acute; Middle Aged; Neoplasms, Multiple Primary; Oxides; Remission Induction; Tretinoin; Urinary Bladder Neoplasms | 2008 |
Protein kinase C is involved in arsenic trioxide-induced apoptosis and inhibition of proliferation in human bladder cancer cells.
Topics: 1-(5-Isoquinolinesulfonyl)-2-Methylpiperazine; Antineoplastic Agents; Apoptosis; Arsenic Trioxide; Arsenicals; Caspase 3; Cell Cycle; Cell Line, Tumor; Cell Proliferation; Dose-Response Relationship, Drug; Enzyme Activators; Humans; Oxides; Protein Kinase C; Protein Kinase Inhibitors; Signal Transduction; Tetradecanoylphorbol Acetate; Time Factors; Urinary Bladder Neoplasms | 2009 |
Keratin 6 expression correlates to areas of squamous differentiation in multiple independent isolates of As(+3)-induced bladder cancer.
Topics: Animals; Arsenic Trioxide; Arsenicals; Biomarkers, Tumor; Carcinogens; Carcinoma, Transitional Cell; Cell Line, Transformed; Cell Line, Tumor; Cell Transformation, Neoplastic; Gene Expression Regulation, Neoplastic; Humans; Keratin-6; Mice; Mice, Nude; Neoplasm Transplantation; Oxides; Urinary Bladder Neoplasms; Urothelium | 2010 |
Arsenic trioxide downregulates specificity protein (Sp) transcription factors and inhibits bladder cancer cell and tumor growth.
Topics: Animals; Antineoplastic Agents; Apoptosis; Arsenic Trioxide; Arsenicals; Blotting, Western; Cell Proliferation; Down-Regulation; Female; Gene Expression Regulation, Neoplastic; Humans; Mice; Mice, Nude; Oxides; Reactive Oxygen Species; Reverse Transcriptase Polymerase Chain Reaction; RNA, Messenger; Sp Transcription Factors; Tumor Cells, Cultured; Urinary Bladder Neoplasms; Xenograft Model Antitumor Assays | 2010 |
MicroRNA-dependent regulation of PTEN after arsenic trioxide treatment in bladder cancer cell line T24.
Topics: Antineoplastic Agents; Apoptosis; Arsenic Trioxide; Arsenicals; Biomarkers, Tumor; Blotting, Western; Cell Proliferation; Gene Expression Profiling; Gene Expression Regulation, Neoplastic; Humans; Luciferases; MicroRNAs; Oligonucleotide Array Sequence Analysis; Oxides; PTEN Phosphohydrolase; Reverse Transcriptase Polymerase Chain Reaction; RNA, Messenger; Tumor Cells, Cultured; Urinary Bladder Neoplasms | 2011 |
Effects of Tat peptide on intracellular delivery of arsenic trioxide albumin microspheres.
Topics: Arsenic Trioxide; Arsenicals; Base Sequence; Cell Line, Tumor; Drug Carriers; Electrophoresis; Gene Products, tat; Green Fluorescent Proteins; Humans; Microspheres; Molecular Sequence Data; Oxides; Recombinant Fusion Proteins; Serum Albumin, Bovine; Urinary Bladder Neoplasms | 2012 |
Cytotoxicity of arsenic trioxide to transitional carcinoma cells.
Topics: Antineoplastic Agents; Arsenic Trioxide; Arsenicals; Buthionine Sulfoximine; Carcinoma, Transitional Cell; Cisplatin; Drug Resistance, Neoplasm; Drug Screening Assays, Antitumor; Glutathione; Humans; Oxides; Tumor Cells, Cultured; Urinary Bladder Neoplasms | 2002 |
Preliminary study of the in vitro growth inhibition of human bladder cancer cell line BIU-87 by arsenic trioxide.
Topics: Antineoplastic Agents; Apoptosis; Arsenic Trioxide; Arsenicals; Cell Division; Dose-Response Relationship, Drug; Down-Regulation; Humans; Oxides; Protein-Tyrosine Kinases; Proto-Oncogene Proteins; Proto-Oncogene Proteins c-bcr; Tumor Cells, Cultured; Urinary Bladder Neoplasms | 2000 |
Effect of Ad-p16 combined with CDDP or As2O3 on human bladder cancer cells.
Topics: Adenoviridae; Apoptosis; Arsenic Trioxide; Arsenicals; Cell Cycle; Cisplatin; Cyclin-Dependent Kinase Inhibitor p16; Genetic Vectors; Humans; Oxides; Transfection; Tumor Cells, Cultured; Urinary Bladder Neoplasms | 2003 |
Characterization of molecular events in a series of bladder urothelial carcinoma cell lines with progressive resistance to arsenic trioxide.
Topics: Apoptosis; Arsenic Trioxide; Arsenicals; Cell Cycle Proteins; Cell Line, Tumor; Cell Proliferation; Cyclin-Dependent Kinase Inhibitor p21; DNA-Binding Proteins; Dose-Response Relationship, Drug; Down-Regulation; Drug Evaluation, Preclinical; Drug Resistance, Neoplasm; Electrophoretic Mobility Shift Assay; Forecasting; Glutathione; Humans; Inhibitory Concentration 50; MutS Homolog 2 Protein; NF-kappa B; Oxides; Proto-Oncogene Proteins; Proto-Oncogene Proteins c-bcl-2; Reactive Oxygen Species; Superoxide Dismutase; Transcription Factor AP-1; Transcription Factors; Tumor Suppressor Protein p53; Up-Regulation; Urinary Bladder Neoplasms; Urothelium | 2004 |
Preparation of arsenic trioxide-loaded albuminutes immuno-nanospheres and its specific killing effect on bladder cancer cell in vitro.
Topics: Animals; Antibodies, Monoclonal; Antineoplastic Agents; Apoptosis; Arsenic Trioxide; Arsenicals; Cell Line, Tumor; Cell Survival; Drug Delivery Systems; Fluorescent Antibody Technique; Mice; Mice, Inbred BALB C; Nanotubes; Oxides; Serum Albumin; Urinary Bladder Neoplasms | 2005 |
Long term consequences of arsenical treatment for multiple sclerosis.
Topics: Adult; Arsenic; Arsenic Trioxide; Arsenicals; Carcinoma, Transitional Cell; Humans; Hypertension, Portal; Male; Multiple Sclerosis; Oxides; Urinary Bladder Neoplasms | 1983 |
Apoptosis inducing effects of arsenic trioxide on human bladder cancer cell line BIU-87.
Topics: Antineoplastic Agents; Apoptosis; Arsenic Trioxide; Arsenicals; Cell Division; DNA; Humans; Immunohistochemistry; Oxides; Proto-Oncogene Proteins c-bcl-2; Tumor Cells, Cultured; Urinary Bladder Neoplasms | 2001 |
Arsenic trioxide as a novel anticancer agent against human transitional carcinoma--characterizing its apoptotic pathway.
Topics: Antineoplastic Agents; Apoptosis; Arsenic Trioxide; Arsenicals; Buthionine Sulfoximine; Carcinoma, Transitional Cell; Caspase 3; Caspases; Cisplatin; DNA, Neoplasm; Drug Resistance, Neoplasm; Enzyme Activation; G1 Phase; Humans; Membrane Potentials; Mitochondria; Oxides; Reactive Oxygen Species; Signal Transduction; Tumor Cells, Cultured; Urinary Bladder Neoplasms | 2002 |